RELATING TO INSURANCE -- PRESCRIPTION DRUG BENEFITS
Impact
The implications of S2253 on state laws are significant, particularly concerning the insurance regulation landscape in Rhode Island. By mandating that insurance calculations include all applicable costs—such as those paid out of pocket or covered by third parties—the bill is poised to enhance consumer protection and transparency in the healthcare system. It could also address inequities faced by patients who struggle with rising prescription drug costs by providing a clearer framework for understanding their financial responsibilities.
Summary
Bill S2253 aims to amend Rhode Island's General Laws pertaining to insurance, particularly focusing on 'Prescription Drug Benefits.' The essence of this bill is to calculate the overall contribution of an enrollee towards out-of-pocket maximums or cost-sharing requirements under a health plan. The proposed provisions will account for any costs paid by the enrollee or third parties on their behalf, ensuring a more comprehensive approach in determining what amounts count towards an enrollee's expense limits from January 1, 2027, onward.
Contention
While the intent behind S2253 is largely focused on improving consumer outcomes in the context of healthcare costs, the bill may spark debates regarding its implementation. Opponents may argue that it places additional burdens on insurers and pharmacy benefit managers to comply with these stringent calculations. Furthermore, concerns may arise surrounding the implications for health savings account eligibility under federal law if these changes inadvertently disqualify certain plans or coverage options, creating a potential friction point between state and federal regulations.
Establishes the Wholesale Prescription Drug Importation Program for the importation of wholesale prescription drugs from Canada, to provide savings to Rhode Island consumers.
Establishes the Wholesale Prescription Drug Importation Program for the importation of wholesale prescription drugs from Canada, to provide savings to Rhode Island consumers.
Caps the total amount that a covered person is required to pay for a covered prescription inhaler, prescription device, or prescription equipment to twenty-five dollars ($25.00) per thirty (30) day supply.
Caps the total amount that a covered person is required to pay for a covered prescription inhaler, prescription device, or prescription equipment to twenty-five dollars ($25.00) per thirty (30) day supply.
Directs the state board of pharmacy to annually identify up to fifteen prescription drugs with increased costs and provide the list to the attorney general to obtain reasons for the cost increases.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Provides certain controls over prescription drug costs by imposing transparency, oversight and accountability requirements on commercial insurers and their pharmacy benefit managers.
Sets controls on Medicaid prescription drug costs by imposing transparency and accountability requirements on managed care organizations (MCOs) and their pharmacy benefit managers (PBMs).